Hypercholesterolaemia Clinical Trial
Official title:
The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol
Verified date | May 2014 |
Source | Universiteit Antwerpen |
Contact | n/a |
Is FDA regulated | No |
Health authority | Belgium: Ethics Committee |
Study type | Interventional |
This randomised controlled trial studies the effect of a commercially available nutritional supplement on cholesterol levels in people with metabolic syndrome and elevated cholesterol levels.
Status | Completed |
Enrollment | 50 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - metabolic syndrome according to ATPIII criteria 3 of the following: - waist circumference >88cm (in females) or >102cm (in males) - triglycerides >150mg/dl - HDL <40 (50)mg/dl in males (females) - blood pressure>130/85 or treatment for AHT - glucose >110mg/dl Exclusion Criteria: - pregnancy - treatment with cholesterol lowering drugs |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | University of Antwerp | Antwerp | Belgie |
Lead Sponsor | Collaborator |
---|---|
Universiteit Antwerpen |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | LDL level | 2 months | No | |
Primary | total cholesterol level | 2 months | No | |
Primary | triglyceride level | 2 months | No | |
Primary | HDL level | 2 months | No | |
Secondary | OxLDL | 2 months | No | |
Secondary | BMI | 2 months | No | |
Secondary | malondialdehyde (MDA) | 2 months | No | |
Secondary | 8-OH-deoxyguanosine (8-OHdG) | 2 months | No | |
Secondary | side effects | 2 months | No | |
Secondary | waist circumference | 2 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935674 -
Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
|
Phase 4 | |
Completed |
NCT02890992 -
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
|
Phase 2 | |
Completed |
NCT00653835 -
Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)
|
Phase 4 | |
Recruiting |
NCT06008756 -
MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
|
Phase 3 | |
Completed |
NCT02585778 -
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
|
Phase 3 | |
Completed |
NCT00329173 -
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
|
Phase 3 | |
Completed |
NCT04169386 -
A Study of PCSK9 Inhibitor AK102 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02770131 -
Chart Review of Repatha® in Subjects With Hyperlipidaemia
|
||
Completed |
NCT03510884 -
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
Recruiting |
NCT06275724 -
Specified Drug-use Survey of Leqvio for s.c. Injection.
|
||
Completed |
NCT03415178 -
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
|
Phase 3 | |
Completed |
NCT01779687 -
Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.
|
Phase 1 | |
Completed |
NCT01617655 -
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
|
Phase 3 | |
Completed |
NCT00328523 -
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
|
Phase 3 | |
Completed |
NCT05934292 -
MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)
|
Phase 1 | |
Completed |
NCT01257971 -
Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors
|
N/A | |
Completed |
NCT00163163 -
Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women
|
Phase 3 | |
Completed |
NCT01597700 -
Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.
|
Phase 1 | |
Terminated |
NCT02906124 -
Study to Evaluate the Safety of Repatha® in Pregnancy
|
||
Completed |
NCT01711749 -
Rosuvastatin Calcium Bioequivalence Study - Fast
|
Phase 1 |